Comparative Cancer Risk in Patients With Psoriasis Treated With Adalimumab, Secukinumab, or Ustekinumab
Authors:
- 1 December 2025
- journal article
- Published by American Medical Association (AMA) in JAMA Dermatology
- Vol. 161 (12) , 1289
Abstract
This cohort study estimates 5-year standardized risks for any first cancer among patients being treated with biologics for moderate to severe psoriasis.Keywords
This publication has 6 references indexed in Scilit:
- Are interleukin 17 and interleukin 23 inhibitors associated with malignancies?—Insights from an international population‐based studyJournal of the European Academy of Dermatology and Venereology, 2023
- Detecting Selection Bias in Observational Studies—When Interventions Work Too FastJAMA Internal Medicine, 2023
- Considerations for Pharmacoepidemiological Studies of Drug–Cancer AssociationsBasic & Clinical Pharmacology & Toxicology, 2017
- Risk of cancer in patients with psoriasis on biological therapies: a systematic reviewBritish Journal of Dermatology, 2017
- Malignancy rates in a large cohort of patients with systemically treated psoriasis in a managed care populationJournal of the American Academy of Dermatology, 2017
- The Active Comparator, New User Study Design in Pharmacoepidemiology: Historical Foundations and Contemporary ApplicationCurrent Epidemiology Reports, 2015